Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free APLS Stock Alerts $41.31 -0.69 (-1.64%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals Short Interest DataCurrent Short Volume12,390,000 sharesPrevious Short Volume10,670,000 sharesChange Vs. Previous Month+16.12%Dollar Volume Sold Short$547.51 millionShort Interest Ratio / Days to Cover8.4Last Record DateApril 30, 2024Outstanding Shares121,370,000 sharesPercentage of Shares Shorted10.21%Today's Trading Volume866,626 sharesAverage Trading Volume1,783,417 sharesToday's Volume Vs. Average49% Short Selling Apellis Pharmaceuticals ? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202412,390,000 shares $547.51 million +16.1%N/A8.4 $44.19 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 12,390,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 8.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: Walleye Trading LLC, Ikarian Capital LLC, Jane Street Group LLC, PEAK6 Investments LLC, SG Americas Securities LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, Portman Square Capital LLP, and Perceptive Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 12,390,000 shares, an increase of 16.1% from the previous total of 10,670,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Apellis Pharmaceuticals: BridgeBio Pharma, Inc. (11.52%), Organon & Co. (4.71%), Ionis Pharmaceuticals, Inc. (6.53%), Madrigal Pharmaceuticals, Inc. (18.68%), Alpine Immune Sciences, Inc. (5.67%), Nuvalent, Inc. (20.08%), Cytokinetics, Incorporated (13.51%), Alkermes plc (7.62%), Perrigo Company plc (2.54%), Blueprint Medicines Co. (7.25%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading down $0.69 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: BBIO Short Interest Data OGN Short Interest Data IONS Short Interest Data MDGL Short Interest Data ALPN Short Interest Data NUVL Short Interest Data CYTK Short Interest Data ALKS Short Interest Data PRGO Short Interest Data BPMC Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press